Woziwodzka A, Krychowiak-Masnicka M, Golunski G, Felberg A, Borowik A, Wyrzykowski D
Molecules. 2021; 26(12).
PMID: 34198510
PMC: 8231999.
DOI: 10.3390/molecules26123628.
Gibbon J, Frith J
Clin Auton Res. 2021; 31(4):499-509.
PMID: 34143333
PMC: 8212790.
DOI: 10.1007/s10286-021-00814-5.
Belayneh A, Molla F
Biomed Res Int. 2020; 2020:7909703.
PMID: 32775441
PMC: 7397437.
DOI: 10.1155/2020/7909703.
Emami S, Siahi-Shadbad M, Adibkia K, Barzegar-Jalali M
Bioimpacts. 2018; 8(4):305-320.
PMID: 30397585
PMC: 6209825.
DOI: 10.15171/bi.2018.33.
Arnold A, Ramirez C, Choi L, Okamoto L, Gamboa A, Diedrich A
Front Physiol. 2014; 5:270.
PMID: 25104940
PMC: 4109567.
DOI: 10.3389/fphys.2014.00270.
Refractory caffeine and ergot-induced cervico-cerebral vasospasm and stroke treated with combined medical and endovascular approach.
Miller M, Kumar A, Callison C
Neuroradiology. 2011; 54(1):77-9.
PMID: 21468675
DOI: 10.1007/s00234-011-0859-x.
Economic evaluation of oral sumatriptan compared with oral caffeine/ergotamine for migraine.
EVANS K, Boan J, Evans J, Shuaib A
Pharmacoeconomics. 1997; 12(5):565-77.
PMID: 10174323
DOI: 10.2165/00019053-199712050-00007.
Pharmacological rationale for the clinical use of caffeine.
Sawynok J
Drugs. 1995; 49(1):37-50.
PMID: 7705215
DOI: 10.2165/00003495-199549010-00004.
[Reciprocal action between caffeine, other stimulants and drugs].
CZOK G
Z Ernahrungswiss. 1980; 19(4):290-5.
PMID: 7467488
DOI: 10.1007/BF02023791.
Ergotamine absorption and toxicity.
Orton D, Richardson R
Postgrad Med J. 1982; 58(675):6-11.
PMID: 7088766
PMC: 2426226.
DOI: 10.1136/pgmj.58.675.6.
Low bioavailability of ergotamine tartrate after oral and rectal administration in migraine sufferers.
Ibraheem J, PAALZOW L, Tfelt-Hansen P
Br J Clin Pharmacol. 1983; 16(6):695-9.
PMID: 6419759
PMC: 1428366.
DOI: 10.1111/j.1365-2125.1983.tb02243.x.
Absorption kinetics of dihydroergotoxine following oral administration to man.
Woodcock B, Rietbrock N, Loh W, Habedank W
Br J Clin Pharmacol. 1985; 20(6):603-9.
PMID: 4091992
PMC: 1400840.
DOI: 10.1111/j.1365-2125.1985.tb05118.x.
Clinical pharmacokinetics of ergotamine in migraine and cluster headache.
Perrin V
Clin Pharmacokinet. 1985; 10(4):334-52.
PMID: 3899452
DOI: 10.2165/00003088-198510040-00004.
Methylxanthines and intestinal drug absorption.
Beubler E, Lembeck F
Naunyn Schmiedebergs Arch Pharmacol. 1976; 292(1):73-7.
PMID: 934356
DOI: 10.1007/BF00506492.
Quantitative determination of ergot alkaloids in biological fluids by radioimmunoassay.
Kleimola T
Br J Clin Pharmacol. 1978; 6(3):255-60.
PMID: 687503
PMC: 1429444.
DOI: 10.1111/j.1365-2125.1978.tb04594.x.
Migraine and drug absorption.
Volans G
Clin Pharmacokinet. 1978; 3(4):313-8.
PMID: 354637
DOI: 10.2165/00003088-197803040-00004.
